Antanas Gulbinas

Prof. Antanas Gulbinas

Department of Surgery, Lithuanian University of Health Sciences, Eiveniu 2, 50161 Kaunas, Lithuania
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
ABAneel Bhangu
Aneel Bhangu
AAAdesoji O Ademuyiwa
Adesoji O Ademuyiwa
MAMaria Lorena Aguilera
Maria Lorena Aguilera
PAPhilip Alexander
Philip Alexander
SASara W Al-Saqqa
Sara W Al-Saqqa
RBRuth Blanco
Ruth Blanco
Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully understood. We quantified the burden of SSI after gastrointestinal surgery in countries in all parts of the world. This international, prospective, multicentre cohort study included consecutive patients undergoing elective or emergency gastrointestinal resection within 2-week time periods at any health-care facility in any country. Countries with participating centres were stratified into high-income, middle-income, and low-income groups according to the UN's Human Development Index (HDI). Data variables from the GlobalSurg 1 study and other studies that have been found to affect the likelihood of SSI were entered into risk adjustment models. The primary outcome measure was the 30-day SSI incidence (defined by US Centers for Disease Control and Prevention criteria for superficial and deep incisional SSI). Relationships with explanatory variables were examined using Bayesian multilevel logistic regression models. This trial is registered with ClinicalTrials.gov, number NCT02662231. Between Jan 4, 2016, and July 31, 2016, 13 265 records were submitted for analysis. 12 539 patients from 343 hospitals in 66 countries were included. 7339 (58·5%) patient were from high-HDI countries (193 hospitals in 30 countries), 3918 (31·2%) patients were from middle-HDI countries (82 hospitals in 18 countries), and 1282 (10·2%) patients were from low-HDI countries (68 hospitals in 18 countries). In total, 1538 (12·3%) patients had SSI within 30 days of surgery. The incidence of SSI varied between countries with high (691 [9·4%] of 7339 patients), middle (549 [14·0%] of 3918 patients), and low (298 [23·2%] of 1282) HDI (p<0·001). The highest SSI incidence in each HDI group was after dirty surgery (102 [17·8%] of 574 patients in high-HDI countries; 74 [31·4%] of 236 patients in middle-HDI countries; 72 [39·8%] of 181 patients in low-HDI countries). Following risk factor adjustment, patients in low-HDI countries were at greatest risk of SSI (adjusted odds ratio 1·60, 95% credible interval 1·05-2·37; p=0·030). 132 (21·6%) of 610 patients with an SSI and a microbiology culture result had an infection that was resistant to the prophylactic antibiotic used. Resistant infections were detected in 49 (16·6%) of 295 patients in high-HDI countries, in 37 (19·8%) of 187 patients in middle-HDI countries, and in 46 (35·9%) of 128 patients in low-HDI countries (p<0·001). Countries with a low HDI carry a disproportionately greater burden of SSI than countries with a middle or high HDI and might have higher rates of antibiotic resistance. In view of WHO recommendations on SSI prevention that highlight the absence of high-quality interventional research, urgent, pragmatic, randomised trials based in LMICs are needed to assess measures aiming to reduce this preventable complication. DFID-MRC-Wellcome Trust Joint Global Health Trial Development Grant, National Institute of Health Research Global Health Research Unit Grant.

15 May 2005 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
PBPascal O. Berberat
Pascal O. Berberat
ZDZilvinas Dambrauskas
Zilvinas Dambrauskas
AGAntanas Gulbinas
Antanas Gulbinas
TGThomas Giese
Thomas Giese
NGNathalia Giese
Nathalia Giese
HFHelmut Friess
Helmut Friess
Heme oxygenase-1 (HO-1) is believed to represent a key enzyme for the protection of cells against “stress.” Its overexpression in different types of human cancers supports the notion that HO-1 provides a growth advantage and contributes to cellular resistance against chemotherapy and radiotherapy. Given the poor survival rates of patients with pancreatic cancer due to its aggressive growth behavior and its exceptional resistance to all known forms of anticancer treatment, we have investigated the expression of HO-1 in human pancreatic cancer cells growth behavior and prognosis. Expression of HO-1 was analyzed in human pancreatic cancer samples in comparison with normal pancreas by quantitative PCR, Western blot, and confocal microscopy. The influence of radiotherapy and chemotherapy on HO-1 expression in pancreatic cancer cell lines was evaluated. Furthermore, HO-1 expression was specifically suppressed by small interfering RNA transfection and subsequently the alterations of growth behavior and resistance to anticancer treatment were tested. Human pancreatic cancer showed a 6-fold and 3.5-fold HO-1 up-regulation in comparison to normal pancreas based on mRNA and protein level, respectively (P < 0.05). Cancer tissues revealed marked HO-1 immunoreactivity in tumor cells and in tumor associated immunocytes. Treatment of the pancreatic cancer cell lines with gemcitabine or radiation strongly induced HO-1 expression. Targeted knockdown of HO-1 expression led to pronounced growth inhibition of the pancreatic cancer cells and made tumor cells significantly more sensitive to radiotherapy and chemotherapy. Therefore, specific inhibition of HO-1 expression may be a new option in pancreatic cancer therapy and may be used as sensitizer to chemotherapy and radiotherapy.

18 April 2007 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
PBP. O. Berberat
P. O. Berberat
HIH. Ingold
H. Ingold
AGAntanas Gulbinas
Antanas Gulbinas
Jörg KleeffJörg Kleeff
Jörg Kleeff
MMM. W. Müller
M. W. Müller
MBM. W. Büchler
M. W. Büchler

1 January 2010 in World Journal of Gastroenterology
Verified
Journal Article
Open access
Zilvinas DambrauskasZilvinas Dambrauskas
Zilvinas Dambrauskas
NGNathalia Giese
Nathalia Giese
AGAntanas Gulbinas
Antanas Gulbinas
TGThomas Giese
Thomas Giese
PBPascal O Berberat
Pascal O Berberat
HFHelmut Friess
Helmut Friess
AIM: To study secretion patterns of pro- and anti-inflammatory cytokines, and activation of various cellular subsets of leukocytes in peripheral blood.

9 August 2018 in BMC Surgery
Verified
Journal Article
Open access
PDF file
VEVitalijus Eismontas
Vitalijus Eismontas
ASAlgirdas Slepavicius
Algirdas Slepavicius
VJVinsas Janusonis
Vinsas Janusonis
PZPaulius Zeromskas
Paulius Zeromskas
VBVirgilijus Beisa
Virgilijus Beisa
AMArvydas +37069871761 Martinkenas
Arvydas +37069871761 Martinkenas
Thyroid surgeries are among the most common operations performed in the world. Hypocalcemia following total thyroidectomy is a common complication that is sometimes difficult to correct. The aim of this study is to determine the risk factors for hypocalcemia following total thyroidectomy and their clinical value. From January 2015 through to April 2017, 400 patients were included in this prospective multicenter study. All patients underwent total thyroidectomy due to various thyroid diseases. The following risk factors were analyzed: pre-operative and post-operative biochemical blood parameters, clinical effects and factors related to surgery, the patient, and the disease. Post-operative hypocalcemia developed in 257 patients (64.2%). Of them, 197 patients (76.7%) were diagnosed with asymptomatic hypocalcemia. Clinical symptoms were present in 60 of the 257 patients with hypocalcemia (23.3%). The statistically significant predictors of hypocalcemia were decreased calcium and ionized calcium pre-operatively (p < 0.001), parathyroid hormone on day one following surgery (p < 0.001), thyrotoxicosis <10 years before surgery (odds ratio 1.65, 95% CI 1.01–2.70, p = 0.046), the number of parathyroid glands found during surgery (odds ratio 0.52, 95% CI 0.38–0.70, p < 0.001), ligation of the trunk of the left inferior thyroid artery (odds ratio 2.04, 95% CI 1.27–3.29, p = 0.003), ligation of the trunk of the right inferior thyroid artery (odds ratio 2.37, 95% CI 1.47–3.81, p < 0.001), and the number of transplanted parathyroid glands (odds ratio 1.87, 95% CI 1.12–2.97, p = 0.015). In the multivariate analysis, age (odds ratio 1.05, 95% CI 1.01–1.09, p = 0.029) and gender (odds ratio 5.94, 95% CI 1.13–31.26, p = 0.035) were statistically significant predictors. This study demonstrates that there is a number of different patient (gender, age, and duration of thyrotoxicosis <10 years before surgery) and surgical (number of parathyroid glands found during surgery, decreased calcium and ionized calcium before surgery, parathyroid hormone on day one following surgery, and ligation of the trunk of the left and right inferior thyroid artery) risk factors predictive of hypocalcemia following total thyroidectomy. Optimization of the surgical technique could possibly prevent the occurrence of hypocalcemia after total thyroidectomy in some cases; in other cases, identification of known risk factors post-operatively could permit early detection and effective treatment of these patients.

1 February 2009 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
PBP.O. Berberat
P.O. Berberat
BKB.M. Künzli
B.M. Künzli
AGAntanas Gulbinas
Antanas Gulbinas
TRT. Ramanauskas
T. Ramanauskas
Jörg KleeffJörg Kleeff
Jörg Kleeff
MBM.W. Büchler
M.W. Büchler